01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – POLB 001 to feature in CRS research programme December 8, 2025 – Posted in: Poolbeg Pharma (POLB)

8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme.   Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme supported by…

Continue reading

#HVO hVIVO PLC – MSD to acquire Cidara November 27, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates its client Cidara Therapeutics, Inc (“Cidara” or the “partner”) which has entered into a definitive agreement under which Merck Sharp & Dohme LLC (“MSD”), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO’s unique capabilities in accelerating drug development and validates the…

Continue reading

#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

Continue reading

#POLB Poolbeg Pharma PLC – Interim results for the six months to 30 June 2023 September 13, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023.   Interim Results Highlights and Business Update ·    Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) ·    Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to…

Continue reading